AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03974373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFP removal
Description: The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
Study NCT03040986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03040986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given by mouth (PO)
Study NCT02887547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Study NCT04421209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hcl 40mg Tab
Description: 40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
Study NCT04421209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Study NCT00786344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects.
Study NCT03274648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral butyrate
Description: Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
Study NCT01192828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taurine
Description: Take Taurine for 4 1/2 days, two doses per day
Study NCT00328250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT) delivered over the Internet
Description: CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
Study NCT00328250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral treatment (CBT) delivered over the Internet
Description: CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
Study NCT03822000 — intervention group
Intervention type: OTHER
Intervention: Survival
Description: Elderly patients with fall-induced femoral fracture who were survived.
Study NCT03822000 — intervention group
Intervention type: OTHER
Intervention: Death
Description: Elderly patients with fall-induced femoral fracture who were dead.
Study NCT03011307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: spinal injection of placebo
Study NCT01695694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supporting positive and healthy relationships
Study NCT01695694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community support group
Study NCT02157155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
Study NCT03099876 — intervention group
Intervention type: PROCEDURE
Intervention: treatment period
Description: 7 days treatment or 10 days treatment
Study NCT02275481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
Study NCT02275481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
Study NCT05083793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: The effect of pregabalin on post-operative pain
Study NCT05083793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo one hour before operation
Study NCT01352988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fumaric acid esters
Description: Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
Study NCT02283710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 600 mg BD
Study NCT02283710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: obtaining ideal body weight by calorie restriction diet and programmed physical activity.
Study NCT03543592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3 dimensional ultrasonography and Doppler
Description: Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
Study NCT03274648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
Study NCT03274648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: Patients follow the habitual diet
Study NCT02822599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaStAP
Description: To decrease post-operative bleeding volume.
Study NCT02822599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo consisting of normal saline 0.9%
Study NCT03706872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
Study NCT02560155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% nasal ointement
Description: Mupirocin nasal ointement 2x/d for 5 days preoperatively
Study NCT02560155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine sol 4%
Description: Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
Study NCT04069026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral application of study drug daily in a predefined dose escalation scheme.
Study NCT04069026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
Study NCT02622217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study NCT01508182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
Study NCT01038609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Study NCT01038609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT00638456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide plus Prevacid
Description: Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Study NCT00638456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus Prevacid
Description: Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Study NCT01038609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Extended Release
Study NCT01038609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03762785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized Dexmedetomidine
Description: inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 80 mg or matching Placebo
Description: MT203 80 mg or matching placebo injection
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 80 mg or matching Placebo
Description: MT203 80 mg or matching placebo injection
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 300 mg or matching placebo
Description: MT203 300 mg or matching placebo injection
Study NCT02354599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 300 mg or matching placebo
Description: MT203 300 mg or matching placebo injection
Study NCT01089075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 20 mg po for 7 days (2 tablets)
Study NCT03806075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second generation sequencing
Description: Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
Study NCT03806075 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 16s rRNA gene sequencing
Description: Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
Study NCT03806075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16s rRNA gene sequencing
Description: Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
Study NCT00671437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Study NCT00671437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT03879421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated corneal collagen cross linking
Description: This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
Study NCT03203733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooral™
Description: An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
Study NCT03203733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Oral cooling by ice chips or crushed ice or ice pop
Study NCT01440881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: infuses at 0.01MCG/KG/min for 48 hours
Study NCT01440881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infuses at 0.01MCG/KG/min for 48 hours
Study NCT02999152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and urines samples
Description: For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy.
Study NCT03970616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
Study NCT03970616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg every 28 days
Study NCT00634790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
Study NCT02880150 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stress test
Study NCT00242593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg twice daily oral rosiglitazone or placebo pill for 18 months
Study NCT00242593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg twice daily oral rosiglitazone or placebo pill for 18 months
Study NCT02726945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
Study NCT02726945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study NCT01310829 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
Study NCT01310829 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physiological Measurements
Description: Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
Study NCT01310829 — intervention group
Intervention type: BEHAVIORAL
Intervention: Virtual Reality Scene Viewing
Description: Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
Study NCT01608373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
Study NCT01608373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal lidocaine irrigation group
Description: Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
Study NCT01608373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study NCT03672786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multicentrum
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
Study NCT03672786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multicentrum
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
Study NCT02264080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL2014
Study NCT02264080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02784769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of skin autofluorescence
Study NCT02784769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy collection
Study NCT00785174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
Study NCT00785174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive pressure support ventilation
Description: noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
Study NCT00785174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive pressure support ventilation
Description: noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
Study NCT03289117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel gel installation device procedure
Description: Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
Study NCT03289117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard procedure
Description: Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
Study NCT01191346 — intervention group
Intervention type: OTHER
Intervention: 3T MRI
Description: 3T MRI in addition to standard 1.5T MRI for treatment planning
Study NCT01720238 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: 0.5mg qd
Study NCT01720238 — intervention group
Intervention type: DRUG
Intervention: Lamivudine plus Adefovir Dipivoxil
Description: Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
Study NCT01872013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study NCT01872013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02356679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eupasidin-s Tab
Description: three times per day, 1 tab for each time, PO, during 2weeks
Study NCT02356679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stillen Tab.
Description: three times per day, 1 tab for each time, PO, during 2weeks